TAT-10: A comparative evaluation of Ac225 and Bi213 as therapeutic radioisotopes for targeted alpha therapy

Kanazawa, Japan (UroToday.com) This is an editorial talk on the relative advantages of Ac225 and Bi213 for targeted alpha therapy. Some factors that seem like obvious advantages for one over the other might be ameliorated by various other effects. For example, the Ac225 decay chain releases four alpha particles whereas Bi213 has only one.

However, the first alpha decay of Ac225 generated enough recoil for the daughter nucleus to break its bond to the conjugate. This is doubly bad since not only are alphas removed from the target site, but the long-lived daughter is now free to travel throughout the body causing damage to healthy tissue. Maximum tolerated dose and therapeutic gain are other comparison endpoints. Cost considerations for preclinical and clinical trials as well as clinical use are relevant.

Considering all these factors, Ac225 is still found to have better or equal performance to Bi213 at much lower cost.

Presented By: Barry Allen from Faculty of Medicine, University of Western Sydney, NSW Australia

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe